A case report describes a 72-year-old patient with Parkinson's disease who developed fatal serotonin syndrome. The patient was on a stable regimen of the monoamine oxidase-B inhibitor rasagiline and received sequential administration of two selective serotonin reuptake inhibitors (sertraline and escitalopram). No comparator was reported in this single-patient case.
The patient developed serotonin syndrome with severe clinical manifestations including rhabdomyolysis, acute hepatic and renal injury, and a disseminated intravascular coagulation-like state, leading to multiple organ failure and death. Pharmacogenomic testing revealed a homozygous CYP2D6*10/*10 genotype, conferring an intermediate metabolizer phenotype.
Safety findings were limited to this single case, with the adverse event being fatal serotonin syndrome and its severe complications. No data on tolerability or discontinuations were reported.
Key limitations include the nature of a single case report, which cannot establish causality or generalizability. The findings are not applicable to broader populations. Practice relevance is restrained: this case underscores the importance of caution when combining serotonergic agents, particularly in patients with complex polypharmacy. It serves as a reminder that even selective MAO-B inhibitors like rasagiline may interact with SSRIs, and pharmacogenetic factors like CYP2D6 status may contribute to individual risk.
Doctors published a detailed report about a single 72-year-old patient with Parkinson's disease. The patient was taking a stable dose of the Parkinson's medication rasagiline. They were then given two different antidepressant medications, sertraline and escitalopram, one after the other. The patient developed a severe and ultimately fatal condition called serotonin syndrome. This is a dangerous drug reaction where too much serotonin builds up in the body. The patient's illness involved severe muscle breakdown, sudden liver and kidney injury, and a serious blood clotting problem, leading to multiple organ failure. Genetic testing after the event showed the patient had a specific genetic makeup (CYP2D6*10/*10 genotype) that made them an 'intermediate metabolizer.' This means their body may have processed the antidepressant medications more slowly than average, potentially contributing to the toxic buildup. It is crucial to understand that this is a report of just one person's tragic experience. While it serves as a serious warning, we cannot know from one case how often this might happen to others. The report highlights that combining certain medications, especially in people with specific genetic profiles, requires extreme caution. Readers should see this as an important reminder to always tell all their doctors about every medication and supplement they are taking, and to ask questions about potential interactions, especially when starting a new drug.
What this means for you: A single case warns of a fatal drug interaction risk when combining certain Parkinson's and antidepressant medications, especially with a specific genetic trait.
View Original Abstract ↓
Serotonin syndrome (SS) is a potentially life-threatening condition resulting from excessive serotonergic activity in the central nervous system. We present a fatal case of SS complicated by multiple organ failure in a 72-year−old patient with Parkinson’s disease following the sequential administration of two selective serotonin reuptake inhibitors (sertraline and escitalopram) while on a stable regimen of the monoamine oxidase-B inhibitor rasagiline. Pharmacogenomic testing revealed a homozygous CYP2D6*10/*10 genotype, conferring an intermediate metabolizer phenotype, which is postulated to have contributed to serotonergic drug accumulation and resultant toxicity in combination with other significant pharmacodynamic and pharmacokinetic interactions. This case was distinguished by three key features: first, the sequential serotonergic challenge from two different SSRIs in combination with rasagiline; second, the unprecedented severity of clinical manifestations, including rhabdomyolysis, acute hepatic and renal injury, and a disseminated intravascular coagulation-like state; and finally, the pharmacogenetic findings that provide a partial mechanistic explanation for the extreme drug sensitivity. This report underscores the critical importance of pre-emptive pharmacogenomic screening in patients receiving complex polypharmacy, particularly when combining drugs with serotonergic properties. It also serves as a critical warning that even selective MAO-B inhibitors can precipitate life-threatening interactions with SSRIs in genetically susceptible individuals, thereby informing more stringent personalized therapeutic strategies.
